Targeting of Protein Kinase CK2 in Acute Myeloid Leukemia Cells Using the Clinical-Grade Synthetic-Peptide CIGB-300

Protein kinase CK2 has emerged as an attractive therapeutic target in acute myeloid leukemia (AML), an advent that becomes particularly relevant since the treatment of this hematological neoplasia remains challenging. Here we explored for the first time the effect of the clinical-grade peptide-based...

Descripción completa

Detalles Bibliográficos
Autores principales: Rosales, Mauro, Pérez, George V., Ramón, Ailyn C., Cruz, Yiliam, Rodríguez-Ulloa, Arielis, Besada, Vladimir, Ramos, Yassel, Vázquez-Blomquist, Dania, Caballero, Evelin, Aguilar, Daylen, González, Luis J., Zettl, Katharina, Wiśniewski, Jacek R., Yang, Ke, Perera, Yasser, Perea, Silvio E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8301452/
https://www.ncbi.nlm.nih.gov/pubmed/34356831
http://dx.doi.org/10.3390/biomedicines9070766

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8301452/
https://www.ncbi.nlm.nih.gov/pubmed/34356831
http://dx.doi.org/10.3390/biomedicines9070766

Ejemplares similares